Table 1 Patient demographics and baseline characteristics

Number of Patients

890

530

157

Female Gender, n (%)

773 (86.8%)

404 (76.2%)

121 (77.0%)

Mean (SD) Age, years

55.8 (13.5)

57.7 (13.0)

56.3 (12.3)

Mean (SD) Weight, Kg

75.4 (19.22)

76.8 (19.4)

78.4 (21.8)

Positive Rheumatoid Factor, %

68.4%

60.4%

58.6%

 Mean (SD)

9.8 (9.98)

8.0 (7.61)

6.5 (8.76)

 Median

6.0

4.9

6.0

 Mean (SD)

2.1 (1.41)

2.3 (1.08)

2.5 (0.97)

 DMARDs

87.2%

94.5%

98.7%

 NSAIDs

59.7%

48.3%

54.8%

 Corticosteroids

47.9%

52.8%

46.5%

 Methotrexate

70.4%

84.7%

92.4%

 DMARDs

89.3%

88.6%

88.5%

 NSAIDs

53.4%

43.8%

49.0%

 Corticosteroids

36.9%

33.0%

28.7%

 Methotrexate

71.1%

67.4%

68.2%

Bio-naive, %

93.7%

86.2%

80.3%

DAS 28 CRP^a

5.3 (1.37)

4.5 (1.2)

4.1 (1.0)

DAS 28 ESR^a

5.7 (1.49)

4.7 (1.40)

4.4 (1.16)

TJC^a

12.3 (8.11)

9.5 (7.0)

9.2 (6.6)

SJC^a

10.4 (7.04)

8.1 (5.7)

6.7 (4.8)

PtGA^a

60.2 (24.12)

56.8 (25.2)

59.2 (25.2)

MDGA^a

6.4 (2.15)

5.9 (2.2)

5.2 (2.5)

HAQ^a

1.6 (0.70)

1.3 (0.7)

1.3 (0.7)

Pain, VAS^a

57.2 (23.99)

55.2 (25.6)

58.2 (28.0)

CRP, mg/L^a

18.2 (23.42)

15.4 (31.4)

20.1 (37.4)

ESR, mm/hr^a

32.2 (24.16)

24.2 (20.6)

26.4 (18.6)

Morning stiffness, min^a

65.3 (45.51)

54.4 (43.8)

60.3 (45.7)